Abstract #0402

Sodium MRI at 7 Tesla as quantitative biomarker to assess tumor heterogeneity and histologic subtypes in glioma patients

Daniel Paech¹, Sebastian Regnery², Nicolas Behl³, Tanja Platt³, Nina Weinfurtner¹, Mark Edward Ladd³, Jürgen Debus², Sebastian Adeberg², and Heinz-Peter Schlemmer¹

¹Radiology, German Cancer Research Center, Heidelberg, Germany, ²Radiooncology, University Hospital Heidelberg, Heidelberg, Germany, ³Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany

²³Na MRI provides information on physiologic and pathophysiologically altered tissue sodium concentrations in vivo. In this prospective trial, we investigated the potential of ²³Na MRI at 7.0 Tesla to predict the tumor grade and genetic subtypes (such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation) in a study cohort of 28 glioma patients. We show that that the quantitative ²³Na signal correlates with tissue-specific tumor subcompartments and that the contrast may allow non-invasive assessment of the tumor grade and IDH mutation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here